RBC Capital has revised its price target for Tandem Diabetes (TNDM, Financial), lowering it from $55 to $45 while maintaining an Outperform rating. This update is part of a comprehensive review that previews first-quarter outcomes in the medical device sector.
Despite the downward revision, the firm anticipates that the underlying procedure volume and capital placements for the first quarter have shown strong performance, influenced by typical seasonal trends. This performance is expected to help the companies within the report's scope, including Tandem Diabetes, surpass market expectations for the quarter.
Additionally, fluctuations in foreign exchange rates are increasingly benefiting large-cap medical device companies, particularly those with significant international operations. However, these FX movements are not yet reflected in the consensus forecasts for the first quarter or for 2025.
Regarding tariffs, RBC Capital notes that the impact is likely to be clarified by several companies. Many of the firms covered in the report have either minimized tariff exposure due to a significant U.S. manufacturing base or have less relative exposure compared to other major players in the industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 21 analysts, the average target price for Tandem Diabetes Care Inc (TNDM, Financial) is $40.81 with a high estimate of $75.00 and a low estimate of $18.00. The average target implies an upside of 139.63% from the current price of $17.03. More detailed estimate data can be found on the Tandem Diabetes Care Inc (TNDM) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, Tandem Diabetes Care Inc's (TNDM, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Tandem Diabetes Care Inc (TNDM, Financial) in one year is $50.52, suggesting a upside of 196.65% from the current price of $17.03. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Tandem Diabetes Care Inc (TNDM) Summary page.
